CoChat
Sign Up
Cited by 39

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Stimulation of the Retinoid X Receptor Facilitates Beta-Amyloid Clearance Across the Blood–Brain Barrier

Bachmeier, Corbin, Beaulieu-Abdelahad, David, Crawford, Fiona, Mullan, Michael, Paris, Daniel·2013·Journal of Molecular Neuroscience
DOI 10.1007/s12031-012-9866-6
Open this paper in CoChat — free account

Abstract

Alzheimer's disease (AD) is a neurodegenerative process characterized, in part, by the accumulation of beta-amyloid proteins (Aβ) in the brain. Evidence now suggests that the excessive Aβ accumulation is the result of impaired clearance from the brain. Recent studies have indicated that retinoid X receptor (RXR) activation stimulates the metabolic clearance of Aβ and rapidly reverses Aβ-induced behavioral deficits, doing so in an apoE-dependent manner. Previously, we reported that soluble apoE (i.e., not bound to Aβ) facilitated Aβ transit across the blood-brain barrier (BBB). As Aβ clearance from the brain involves both metabolic and BBB-mediated processes, the current studies investigated the impact of RXR stimulation on Aβ clearance across the BBB. Treatment with RXR agonists increased Aβ clearance across the BBB both in vitro and in vivo. Moreover, this processes appeared to involve apoE as RXR agonism did not stimulate Aβ BBB clearance when apoE was absent. Thus, RXR activation could mitigate Aβ brain burden by promoting both the metabolic and BBB clearance of Aβ, offering a novel approach to the treatment of AD.

Overview

Integrity signals

Registry

Crossref · 10.1007/s12031-012-9866-6

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 33

  1. Bachmeier C, Mullan M, Paris D (2010) Characterization and use of human brain microvascular endothelial cells to examine beta-amyloid exchange in the blood–brain barrier. Cytotechnology 62:519–529 · DOI
  2. Bachmeier C, Paris D, Beaulieu-Abdelahad D, Mouzon B, Mullan M, Crawford F (2012) A multifaceted role for apoe in the clearance of beta-amyloid across the blood–brain barrier. Neurodegener Dis. doi: 10.1159/000337231 · DOI
  3. Bachmeier CJ, Beaulieu-Abdelahad D, Mullan MJ, Paris D (2011) Epitope-dependent effects of beta-amyloid antibodies on beta-amyloid clearance in an in vitro model of the blood–brain barrier. Microcirculation 18:373–379 · DOI
  4. Burgess JW, Marcel YL (2001) Dynamic and stable pools of apoE differ functionally at the hepg2 cell surface. J Lipid Res 42:1413–1420 · DOI
  5. Camacho IE, Serneels L, Spittaels K, Merchiers P, Dominguez D, De Strooper B (2004) Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. J Neurosci 24:10908–10917 · DOI
  6. Chan GN, Hoque MT, Cummins CL, Bendayan R (2011) Regulation of p-glycoprotein by orphan nuclear receptors in human brain microvessel endothelial cells. J Neurochem 118:163–175 · DOI
  7. Dawson MI, Xia Z (2012) The retinoid x receptors and their ligands. Biochim Biophys Acta 1821:21–56 · DOI
  8. Do TM, Noel-Hudson MS, Ribes S et al (2012) Abcg2- and abcg4-mediated efflux of amyloid-beta peptide 1-40 at the mouse blood–brain barrier. J Alzheimers Dis 30:155–166 · DOI
  9. Fitz NF, Cronican A, Pham T et al (2010) Liver x receptor agonist treatment ameliorates amyloid pathology and memory deficits caused by high-fat diet in app 23 mice. J Neurosci 30:6862–6872 · DOI · Paper page
  10. Gauthier A, Vassiliou G, Benoist F, McPherson R (2003) Adipocyte low density lipoprotein receptor-related protein gene expression and function is regulated by peroxisome proliferator-activated receptor gamma. J Biol Chem 278:11945–11953 · DOI · Paper page
  11. Hessel S, Lampen A (2010) All-trans retinoic acid enhances the transport of phase ii metabolites of benzo[a]pyrene by inducing the breast cancer resistance protein expression in caco-2 cells. Toxicol Lett 197:151–155 · DOI
  12. Kockx M, Guo DL, Huby T et al (2007) Secretion of apolipoprotein e from macrophages occurs via a protein kinase A and calcium-dependent pathway along the microtubule network. Circ Res 101:607–616 · DOI
  13. Kockx M, Jessup W, Kritharides L (2008) Regulation of endogenous apolipoprotein E secretion by macrophages. Arterioscler Thromb Vasc Biol 28:1060–1067 · DOI · Paper page
  14. Krohn M, Lange C, Hofrichter J et al (2011) Cerebral amyloid-beta proteostasis is regulated by the membrane transport protein abcc1 in mice. J Clin Invest 121:3924–3931 · DOI · Paper page
  15. Kuhnke D, Jedlitschky G, Grube M et al (2007) Mdr1-p-glycoprotein (abcb1) mediates transport of Alzheimer’s amyloid-beta peptides–implications for the mechanisms of abeta clearance at the blood–brain barrier. Brain Pathol 17:347–353 · DOI
  16. Lefebvre P, Benomar Y, Staels B (2010) Retinoid x receptors: common heterodimerization partners with distinct functions. Trends Endocrinol Metab 21:676–683 · DOI
  17. Liang Y, Lin S, Beyer TP et al (2004) A liver x receptor and retinoid x receptor heterodimer mediates apolipoprotein e expression, secretion and cholesterol homeostasis in astrocytes. J Neurochem 88:623–634 · DOI · Paper page
  18. Lucas M, Mazzone T (1996) Cell surface proteoglycans modulate net synthesis and secretion of macrophage apolipoprotein E. J Biol Chem 271:13454–13460 · DOI
  19. McLean CA, Cherny RA, Fraser FW et al (1999) Soluble pool of abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease. Ann Neurol 46:860–866 · DOI
  20. Mehta PD (2007) Amyloid beta protein as a marker or risk factor of Alzheimer’s disease. Curr Alzheimer Res 4:359–363 · DOI
  21. Nordberg A (2008) Amyloid imaging in Alzheimer’s disease. Neuropsychologia 46:1636–1641 · DOI
  22. Piedrahita JA, Zhang SH, Hagaman JR, Oliver PM, Maeda N (1992) Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci USA 89:4471–4475 · DOI · Paper page
  23. Podlisny MB, Ostaszewski BL, Squazzo SL et al (1995) Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J Biol Chem 270:9564–9570 · DOI
  24. Podlisny MB, Walsh DM, Amarante P et al (1998) Oligomerization of endogenous and synthetic amyloid beta-protein at nanomolar levels in cell culture and stabilization of monomer by Congo red. Biochemistry 37:3602–3611 · DOI
  25. Suon S, Zhao J, Villarreal SA et al (2010) Systemic treatment with liver x receptor agonists raises apolipoprotein E, cholesterol, and amyloid-beta peptides in the cerebral spinal fluid of rats. Mol Neurodegener 5:44 · DOI
  26. Tai LM, Loughlin AJ, Male DK, Romero IA (2009) P-glycoprotein and breast cancer resistance protein restrict apical-to-basolateral permeability of human brain endothelium to amyloid-beta. J Cereb Blood Flow Metab 29:1079–1083 · DOI · Paper page
  27. Tao H, Aakula S, Abumrad NN, Hajri T (2010) Peroxisome proliferator-activated receptor-gamma regulates the expression and function of very-low-density lipoprotein receptor. Am J Physiol Endocrinol Metab 298:E68–E79 · DOI
  28. Tsukuda K, Mogi M, Iwanami J et al (2009) Cognitive deficit in amyloid-beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-gamma activation. Hypertension 54:782–787 · DOI
  29. Vogelgesang S, Cascorbi I, Schroeder E et al (2002) Deposition of Alzheimer’s beta-amyloid is inversely correlated with p-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 12:535–541 · DOI
  30. Weller RO, Boche D, Nicoll JA (2009) Microvasculature changes and cerebral amyloid angiopathy in Alzheimer’s disease and their potential impact on therapy. Acta Neuropathol 118:87–102 · DOI · Paper page
  31. Wells JM, Amaratunga A, McKenna DC, Abraham CR, Fine RE (1995) Amyloid β-protein precursor and apolipoprotein e production in cultured cerebral endothelial cells isolated from brains of patients with neurodegenerative disorders at autopsy. Amyloid 2:229–233 · DOI
  32. Zelcer N, Khanlou N, Clare R et al (2007) Attenuation of neuroinflammation and Alzheimer’s disease pathology by liver x receptors. Proc Natl Acad Sci USA 104:10601–10606 · DOI · Paper page
  33. Zhong N, Weisgraber KH (2009) Understanding the basis for the association of apoe4 with Alzheimer’s disease: opening the door for therapeutic approaches. Curr Alzheimer Res 6:415–418 · DOI

Cited by

Sorted by citations

Metadata

Authors
Bachmeier, C., Beaulieu-Abdelahad, D., Crawford, F., Mullan, M., & Paris, D.
Venue
Journal of Molecular Neuroscience
Publisher
Springer Science and Business Media LLC
Published
2012-08-14
Volume
49
Issue
2
Pages
270-276
ISSN
  • 0895-8696
  • 1559-1166
DOI
10.1007/s12031-012-9866-6
Cited by
39
References
12
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review